{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T16:25:00Z","timestamp":1786119900414,"version":"build-2736575974"},"reference-count":24,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2012,10]]},"DOI":"10.1097\/coc.0b013e318219863b","type":"journal-article","created":{"date-parts":[[2011,5,7]],"date-time":"2011-05-07T03:26:14Z","timestamp":1304738774000},"page":"418-423","source":"Crossref","is-referenced-by-count":19,"title":["Gemcitabine and Docetaxel for Hepatocellular Carcinoma"],"prefix":"10.1097","volume":"35","author":[{"given":"Steven R.","family":"Alberts","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joel M.","family":"Reid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruce W.","family":"Morlan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gist H.","family":"Farr","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John K.","family":"Camoriano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David B.","family":"Johnson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James R.","family":"Enger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas E.","family":"Seay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"George P.","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-3-20210128","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/S0305-7372(96)90014-6","article-title":"Clinical, toxicological and pharmacological aspects of gemcitabine.","volume":"22","author":"Guchelaar","year":"1996","journal-title":"Cancer Treat Rev"},{"key":"R2-3-20210128","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1016\/S0168-8278(98)80326-7","article-title":"Antitumor effect of the nucleoside analogs 2-chlorodeoxyadenosine and 2,2-difluorodeoxycytidine on human hepatoma HepG2 cells.","volume":"28","author":"Graziadei","year":"1998","journal-title":"J Hepatol"},{"key":"R3-3-20210128","first-page":"115","article-title":"A phase II study of gemcitabine and cisplatin in patients with advanced hepatocellular carcinoma.","volume":"26","author":"Parikh","year":"2005","journal-title":"Trop Gastroenterol"},{"key":"R4-3-20210128","doi-asserted-by":"crossref","first-page":"1865","DOI":"10.1038\/sj.bjc.6601369","article-title":"Prospective randomised phase II study of gemcitabine at standard or fixed dose rate schedule in unresectable hepatocellular carcinoma.","volume":"89","author":"Guan","year":"2003","journal-title":"Br J Cancer"},{"key":"R5-3-20210128","doi-asserted-by":"crossref","first-page":"3186","DOI":"10.1002\/cncr.10607","article-title":"A phase II trial of gemcitabine in patients with advanced hepatocellular carcinoma.","volume":"94","author":"Fuchs","year":"2002","journal-title":"Cancer"},{"key":"R6-3-20210128","first-page":"783","article-title":"Phase II study of systemic gemcitabine chemotherapy for advanced unresectable hepatobiliary carcinomas.","volume":"48","author":"Kubicka","year":"2001","journal-title":"Hepato Gastroenterol"},{"key":"R7-3-20210128","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1159\/000058526","article-title":"Treatment of advanced hepatocellular carcinoma with biweekly high-dose gemcitabine.","volume":"60","author":"Ulrich-Pur","year":"2001","journal-title":"Oncology"},{"key":"R8-3-20210128","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1002\/1097-0142(20000815)89:4<750::AID-CNCR5>3.0.CO;2-R","article-title":"Phase II study of gemcitabine in patients with advanced hepatocellular carcinoma.","volume":"89","author":"Yang","year":"2000","journal-title":"Cancer"},{"key":"R9-3-20210128","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1097\/00001813-199506000-00002","article-title":"Docetaxel (Taxotere), a review of preclinical and clinical experience. Part II: Clinical experience. erratum appears in Anticancer Drugs 1995;6(4):618.","volume":"6","author":"van Oosterom","year":"1995","journal-title":"Anticancer Drugs"},{"key":"R10-3-20210128","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1007\/s002800100317","article-title":"Phase I and pharmacokinetic study of two sequences of gemcitabine and docetaxel administered weekly to patients with advanced cancer.","volume":"48","author":"Bhargava","year":"2001","journal-title":"Cancer Chemother Pharmacol"},{"key":"R11-3-20210128","doi-asserted-by":"crossref","first-page":"99","DOI":"10.2165\/00003088-199936020-00002","article-title":"Clinical pharmacokinetics of docetaxel.","volume":"36","author":"Clarke","year":"1999","journal-title":"Clin Pharmacokinetics"},{"key":"R12-3-20210128","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1023\/A:1010687017717","article-title":"Population pharmacokinetics and pharmacokinetic-pharmacodynamic relationships for docetaxel.","volume":"19","author":"Bruno","year":"2001","journal-title":"Invest New Drugs"},{"key":"R13-3-20210128","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/S0959-8049(97)00340-7","article-title":"Pharmacokinetics of anticancer agents in patients with impaired liver function.","volume":"34","author":"Donelli","year":"1998","journal-title":"Eur J Cancer"},{"key":"R16-3-20210128","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1007\/BF02353487","article-title":"A population pharmacokinetic model for docetaxel (Taxotere): model building and validation.","volume":"24","author":"Bruno","year":"1996","journal-title":"J Pharmacokinetics Biopharmaceutics"},{"key":"R17-3-20210128","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1200\/JCO.2000.18.5.1116","article-title":"Phase I and pharmacokinetic study of irinotecan and docetaxel in patients with advanced solid tumors: preliminary evidence of clinical activity.","volume":"18","author":"Adjei","year":"2000","journal-title":"J Clin Oncol"},{"key":"R18-3-20210128","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/S0169-2607(98)00067-4","article-title":"Xpose--an S-PLUS based population pharmacokineticpharmacodynamic model building aid for NONMEM.","volume":"58","author":"Jonsson","year":"1999","journal-title":"Comp Method Prog Biomed"},{"key":"R19-3-20210128","doi-asserted-by":"crossref","first-page":"1463","DOI":"10.1023\/A:1011970125687","article-title":"Automated covariate model building within NONMEM.","volume":"15","author":"Jonsson","year":"1998","journal-title":"Pharmaceutical Res"},{"key":"R20-3-20210128","first-page":"487","article-title":"Doxorubicin (75 mgm2) for hepatocellular carcinoma: clinical and pharmacokinetic results.","volume":"68","author":"Chlebowski","year":"1984","journal-title":"Cancer Treat Report"},{"key":"R21-3-20210128","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1002\/1097-0142(19880801)62:3<479::AID-CNCR2820620306>3.0.CO;2-L","article-title":"Doxorubicin versus no antitumor therapy in inoperable hepatocellular carcinoma. A prospective randomized trial.","volume":"62","author":"Lai","year":"1988","journal-title":"Cancer"},{"key":"R22-3-20210128","doi-asserted-by":"crossref","first-page":"2751","DOI":"10.1002\/1097-0142(19851215)56:12<2751::AID-CNCR2820561205>3.0.CO;2-O","article-title":"Adriamycin treatment for hepatocellular carcinoma. Experience with 109 patients.","volume":"56","author":"Sciarrino","year":"1985","journal-title":"Cancer"},{"key":"R23-3-20210128","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1016\/S0093-7754(01)90144-7","article-title":"Systemic therapy for hepatocellular carcinoma.","volume":"28","author":"Leung","year":"2001","journal-title":"Semin Oncol"},{"key":"R24-3-20210128","doi-asserted-by":"crossref","first-page":"1771","DOI":"10.1093\/annonc\/mdf303","article-title":"Gemcitabine and doxorubicin for the treatment of patients with advanced hepatocellular carcinoma: a phase I-II trial.","volume":"13","author":"Yang","year":"2002","journal-title":"Ann Oncol"},{"key":"R25-3-20210128","doi-asserted-by":"crossref","first-page":"1384","DOI":"10.1002\/cncr.22532","article-title":"Gemcitabine plus oxaliplatin (GEMOX) in patients with advanced hepatocellular carcinoma (HCC): results of a phase II study.","volume":"109","author":"Louafi","year":"2007","journal-title":"Cancer"},{"key":"R26-3-20210128","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1093\/jnci\/djn134","article-title":"Design and endpoints of clinical trials in hepatocellular carcinoma.","volume":"100","author":"Llovet","year":"2008","journal-title":"J Natl Cancer Inst"}],"container-title":["American Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/00000421-201210000-00003","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T19:27:35Z","timestamp":1786044455000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/00000421-201210000-00003"}},"subtitle":["A Phase II North Central Cancer Treatment Group Clinical Trial"],"short-title":[],"issued":{"date-parts":[[2012,10]]},"references-count":24,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2012]]}},"URL":"https:\/\/doi.org\/10.1097\/coc.0b013e318219863b","relation":{},"ISSN":["0277-3732"],"issn-type":[{"value":"0277-3732","type":"print"}],"subject":[],"published":{"date-parts":[[2012,10]]}}}